Yes, Repatha (evolocumab) is a PCSK9 inhibitor. It belongs to a class of injectable cholesterol-lowering medications that work by blocking a protein called PCSK9, which normally breaks down the receptors your liver uses to pull LDL cholesterol out of your bloodstream. By blocking that protein, Repatha allows more of those receptors to stay active on the surface of liver cells, clearing LDL cholesterol faster and more efficiently.
How Repatha Lowers Cholesterol
Your liver cells have receptors on their surface that grab LDL cholesterol (the “bad” kind) from your blood and remove it from circulation. Normally, a protein called PCSK9 attaches to these receptors and marks them for destruction, reducing the number available to do their job. Over time, fewer active receptors means more LDL stays in your bloodstream.
Repatha is a monoclonal antibody, a lab-made protein designed to intercept PCSK9 before it can reach those receptors. With PCSK9 out of the picture, the receptors recycle back to the liver cell surface instead of being broken down. The result is a significant increase in your liver’s ability to clear LDL from the blood. In clinical trials, Repatha lowered LDL cholesterol by 50% to 60% from baseline, a substantially larger reduction than most oral medications can achieve alone.
FDA-Approved Uses
Repatha is not just a general cholesterol drug. The FDA has approved it for several specific situations:
- Established cardiovascular disease: In adults who have already had a heart attack, stroke, or related event, Repatha is approved to reduce the risk of future heart attacks, strokes, and procedures to reopen blocked arteries.
- Primary hyperlipidemia: For adults with high LDL cholesterol, including an inherited form called heterozygous familial hypercholesterolemia (HeFH), Repatha can be used alongside diet changes and other cholesterol treatments.
- Pediatric use: Children aged 10 and older with HeFH or the more severe homozygous familial hypercholesterolemia (HoFH) can also be prescribed Repatha.
- Homozygous familial hypercholesterolemia: Adults and children 10 and older with this rare, severe genetic condition can use Repatha alongside other cholesterol-lowering therapies.
Where It Fits in Treatment
Repatha is typically not the first medication prescribed for high cholesterol. Current guidelines from the American College of Cardiology and American Heart Association recommend starting with a statin at the highest dose a patient can tolerate. If that isn’t enough, especially for people at very high cardiovascular risk, the next step is adding ezetimibe (another oral cholesterol drug) or a PCSK9 inhibitor like Repatha, or both.
In practice, this means Repatha is most often prescribed for people whose LDL remains stubbornly high despite taking a statin, or for those who can’t tolerate statins due to side effects. It’s also a critical option for people with familial hypercholesterolemia, a genetic condition where LDL levels are dangerously elevated from birth and statins alone rarely bring them under control.
Cardiovascular Benefits Beyond Cholesterol Numbers
Lowering LDL is the mechanism, but the real goal is preventing heart attacks and strokes. The landmark FOURIER trial and its long-term follow-up study showed that Repatha delivers meaningful reductions in major cardiovascular events. Patients with disease in multiple coronary arteries saw a 37% to 38% reduction in events like heart attacks, strokes, and cardiovascular death over the first three years. Those with less extensive disease still experienced a 23% to 28% reduction over the same period. These benefits appeared to grow over time, suggesting that longer use may offer greater protection.
How You Take It
Repatha is a self-administered injection given under the skin, either in the abdomen, thigh, or upper arm. You rotate injection sites each time. There are two dosing options for most patients: 140 mg every two weeks, or 420 mg once a month. Both schedules produce similar cholesterol reductions, so the choice often comes down to personal preference and convenience.
The 420 mg monthly dose can be given as a single injection using a wearable device called the Pushtronex system, which delivers the medication over about five minutes, or as three consecutive injections within a 30-minute window using prefilled syringes or autoinjectors. For patients with homozygous familial hypercholesterolemia who don’t respond adequately to the standard monthly dose, the frequency can be increased to every two weeks.
Storage and Handling
Repatha needs to be kept in the refrigerator between 36°F and 46°F in its original carton. If you need to travel or don’t have refrigerator access, you can store it at room temperature (68°F to 77°F) for up to 30 days. After 30 days at room temperature, any unused medication has to be discarded. Most patients let the prefilled syringe or autoinjector warm to room temperature for about 30 minutes before injecting, which makes the injection more comfortable.
How Repatha Compares to Other PCSK9 Inhibitors
Repatha is one of two injectable PCSK9 inhibitors currently available. The other is alirocumab (Praluent). Both are monoclonal antibodies, both lower LDL by roughly the same percentage (50% to 60%), and both are given as subcutaneous injections on similar schedules. The choice between them often depends on insurance coverage, cost, and prescriber preference rather than meaningful clinical differences. A newer option, inclisiran (Leqvio), works on the same PCSK9 pathway but uses a different mechanism (it stops the liver from making PCSK9 in the first place) and only requires injections twice a year after the initial doses. That one is given in a doctor’s office rather than self-administered at home.